QUOTE AND NEWS
FierceBiotech  Dec 11  Comment 
Takeda, in the process of trimming down its R&D efforts, has inked a collaborative research deal with Australia's Monash University to discover and develop new treatments for gastrointestinal diseases.
GenEng News  Dec 9  Comment 
The Monash Institute of Pharmaceutical Sciences (MIPS), Monash University in Melbourne, Australia, and Takeda Pharmaceutical formed an alliance to develop new medicines to tackle human gastrointestinal diseases. Takeda will fund the initiative...
FierceBiotech  Dec 8  Comment 
In 2008, Takeda made waves in the biotech world when it agreed to pay $8.8 billion for Millennium Pharmaceuticals, a trailblazing outfit from Cambridge, MA. Now, years into integrating its acquisition, Takeda is dropping the Millennium moniker,...
GenEng News  Dec 8  Comment 
Shakespeare’s observation on names: “That which we call a rose by any other name would smell as sweet"—is being taken to heart by Takeda Pharmaceutical, which said today it has rebranded its global oncology business unit from Millennium: The...
MedPage Today  Dec 5  Comment 
(MedPage Today) -- No evidence seen for bladder cancer risk.
FierceBiotech  Dec 1  Comment 
The FDA has branded Takeda's top late-stage drug prospect--ixazomib (MLN9708), a multiple myeloma treatment designed to succeed the top-selling blockbuster Velcade--as a "breakthrough" therapy deserving VIP status with regulators.
FiercePharma  Nov 25  Comment 
When Takeda Pharmaceutical faced the patent-cliff blues, it brought in Christophe Weber as president and COO to engineer a revamp. And true to his mission, Weber unveiled a new org chart in September, along with a fresh set of top managers.
FiercePharma  Nov 12  Comment 
Takeda Pharmaceuticals saw a problem with recent obesity drug launches: Cost. Private insurers and public payers were refusing coverage--or foisting big copays onto patients--dragging down new drugs marketed by Vivus and Eisai.




 
TOP CONTRIBUTORS

No more s***. All posts of this qaultiy from now on

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki